{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:20Z","timestamp":1786993700852,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.lungcan.2024.108038","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T18:10:42Z","timestamp":1732644642000},"page":"108038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort"],"prefix":"10.1016","volume":"199","author":[{"given":"Aur\u00e9lie","family":"Swalduz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Beau-Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bayle-Bleuez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8016-7956","authenticated-orcid":false,"given":"Didier","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Fallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Couraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Domblides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-0651","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Lariv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Lerolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-7859","authenticated-orcid":false,"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Missy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6400-7506","authenticated-orcid":false,"given":"Jean-Bernard","family":"Auliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10026","key":"10.1016\/j.lungcan.2024.108038_b0005","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.108038_b0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2018.04.006","article-title":"BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall","volume":"66","author":"Leonetti","year":"2018","journal-title":"Cancer Treat Rev."},{"issue":"14","key":"10.1016\/j.lungcan.2024.108038_b0015","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.3390\/cancers14143472","article-title":"Genomic landscape, clinical features and outcomes of non-small cell lung cancer patients harboring BRAF alterations of distinct functional classes","volume":"14","author":"Di Federico","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2024.108038_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2004.09.022","article-title":"Guilty as charged: B-RAF is a human oncogene","author":"Garnett","year":"2004","journal-title":"Cancer Cell"},{"issue":"6892","key":"10.1016\/j.lungcan.2024.108038_b0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.lungcan.2024.108038_b0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.lungcan.2024.108038_b0035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","article-title":"Targeting BRAF -mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy","volume":"22","author":"Baik","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.lungcan.2024.108038_b0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF\u2013MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2024.108038_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102335","article-title":"How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)","volume":"103","author":"Tabb\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108038_b0050","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12967-019-2036-7","article-title":"The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients","volume":"17","author":"Lin","year":"2019","journal-title":"J. Transl. Med."},{"issue":"26","key":"10.1016\/j.lungcan.2024.108038_b0055","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non\u2013small-cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti","year":"2011","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.lungcan.2024.108038_b0060","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.3390\/cancers12123608","article-title":"Efficacy of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019","volume":"12","author":"Auliac","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.lungcan.2024.108038_b0065","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3390\/cancers14082019","article-title":"Multicenter observational study on metastatic non-small cell lung cancer harboring BRAF mutations: focus on clinical characteristics and treatment outcome of V600E and non-V600E subgroups","volume":"14","author":"Perrone","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2024.108038_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103008","article-title":"A BRAF new world","volume":"152","author":"Frisone","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.lungcan.2024.108038_b0075","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/JTO.0000000000000344","article-title":"Clinical characteristics and course of 63 patients with BRAF mutant lung cancers","volume":"9","author":"Litvak","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.108038_b0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.21037\/tlcr.2019.04.03","article-title":"Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study","volume":"8","author":"Tan","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"issue":"20","key":"10.1016\/j.lungcan.2024.108038_b0085","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1200\/JCO.2012.47.6143","article-title":"Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma","volume":"31","author":"Peters","year":"2013","journal-title":"JCO."},{"issue":"8","key":"10.1016\/j.lungcan.2024.108038_b0090","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108038_b0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2019.10.022","article-title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","volume":"31","author":"Mazieres","year":"2020","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.108038_b0100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/JTO.0000000000000625","article-title":"Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort","volume":"10","author":"Gautschi","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.108038_b0105","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/ijms18071527","article-title":"Role played by signalling pathways in overcoming BRAF inhibitor resistance in melanoma","volume":"18","author":"Chan","year":"2017","journal-title":"IJMS"},{"issue":"7","key":"10.1016\/j.lungcan.2024.108038_b0110","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.108038_b0115","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108038_b0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.108038_b0125","unstructured":"D. Planchard, B. Besse, H.J.M. Groen, S.M.S. Hashemi, J. Mazieres, T.M. Kim, et al. The updated overall survival and genomic analysis from a single-arm phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer."},{"issue":"5","key":"10.1016\/j.lungcan.2024.108038_b0130","article-title":"Clinical outcomes with dabrafenib plus trametinib in a clinical trial versus real-world standard of care in patients with BRAF-mutated advanced NSCLC","volume":"3","author":"Johnson","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"3","key":"10.1016\/j.lungcan.2024.108038_b0145","article-title":"Real-world treatment patterns and effectiveness of targeted and immune checkpoint inhibitor-based systemic therapy in BRAF mutation-positive NSCLC","volume":"4","author":"Gibson","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"21","key":"10.1016\/j.lungcan.2024.108038_b0150","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF V600 -mutant metastatic non\u2013small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2024.108038_b0155","doi-asserted-by":"crossref","unstructured":"G.J. Riely, M-J. Ahn, J. Clarke, I. Dagogo-Jack, E. Felip, F. Gelsomino, et al., LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC), Ann. Oncol. 35, S1246\u2013S1247.","DOI":"10.1016\/j.annonc.2024.08.2298"},{"issue":"2","key":"10.1016\/j.lungcan.2024.108038_b0160","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/j.cllc.2018.10.003","article-title":"Natural disease history, outcomes, and co-mutations in a series of patients with BRAF-mutated non\u2013small-cell lung cancer","volume":"20","author":"Myall","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.108038_b0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2019.04.016","article-title":"Clinical outcomes of non\u2013small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study","volume":"116","author":"Couraud","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"suppl_2","key":"10.1016\/j.lungcan.2024.108038_b0170","first-page":"S802","article-title":"1259MO - Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): an open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)","volume":"35","author":"Planchard","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4S","key":"10.1016\/j.lungcan.2024.108038_b0175","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1556-0864(23)00290-3","article-title":"Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: a real-world multi-center study","volume":"18","author":"Jia","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.108038_b0185","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41419-022-05510-4","article-title":"Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lungcan.2024.108038_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.08.942","article-title":"P1.0439 molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF Non-V600 mutant lung cancers","author":"Offin","year":"2019","journal-title":"J. Thoracic Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.108038_b0195","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","article-title":"Efficacy and safety of anti-PD-1 immunotherapy inpatients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018","volume":"15","author":"Guisier","year":"2020","journal-title":"J. Thorac Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.108038_b0200","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.3390\/cancers12123608","article-title":"Efficacy of dabrafenib plus trametinib combination in patients withBRAFV600E-mutant NSCLC in real-world setting: GFPC 01-2019","volume":"12","author":"Auliac","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:51:50Z","timestamp":1756860710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224005725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"alternative-id":["S0169500224005725"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108038","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108038"}}